Comparative Pharmacology
Head-to-head clinical analysis: PYRIDOXINE versus PYRIDOXINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYRIDOXINE versus PYRIDOXINE HYDROCHLORIDE.
Pyridoxine (Vitamin B6) vs PYRIDOXINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyridoxine is converted to pyridoxal phosphate, a cofactor for enzymes involved in amino acid metabolism, neurotransmitter synthesis, and heme biosynthesis.
Pyridoxine hydrochloride is a water-soluble vitamin that serves as a cofactor for over 100 enzymes involved in amino acid, carbohydrate, and lipid metabolism. It is converted to pyridoxal phosphate, which participates in transamination, deamination, decarboxylation, and other reactions.
50-200 mg orally or intramuscularly once daily; for deficiency, 100-300 mg/day; for pyridoxine-dependent seizures, 50-100 mg intravenously or intramuscularly once.
25-50 mg orally daily for dietary supplementation; 100-200 mg orally daily for vitamin B6 deficiency; 100 mg orally once daily for prophylaxis of neuropathy (e.g., isoniazid therapy); 30-600 mg orally daily in divided doses for pyridoxine-dependent seizures.
None Documented
None Documented
Terminal elimination half-life approximately 15-20 days for pyridoxine stored in tissues; clinical context: after cessation of supplementation, depletion takes weeks to months due to slow release from tissue pools.
Terminal half-life is 15–20 days for pyridoxine and its phosphate esters due to extensive tissue binding and slow release; free pyridoxine half-life 1–2 hours.
Renal: ~50% as pyridoxic acid and other metabolites; biliary/fecal: ~30% as unchanged drug and metabolites; <2% excreted unchanged in urine.
Renal excretion of 4-pyridoxic acid and other metabolites accounts for >90% of elimination; <2% excreted unchanged in urine.
Category A/B
Category C
Vitamin B6
Vitamin B6